Abstract
Aumolertinib, an investigational third-generation EGFR inhibitor (EGFRi), has been developed as a first-line treatment for patients with advanced EGFR mutation-positive NSCLC. Aumolertinib and osimertinib, the only approved third-generation EGFRi for this population, have both demonstrated superior safety and efficacy compared to first-generation EGFRis. As no randomized clinical trial (RCT) has directly compared aumolertinib and osimertinib, we conducted an indirect treatment comparison using first-generation EGFRis as the anchor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
